1  agents, and antibiotics in the treatment of spondylarthropathy.

2 sing spondylitis (AS) and with other related spondylarthropathies.

3  For reactive arthritis and undifferentiated spondylarthropathy, a combination of antibiotics may be

4 stionnaire disability index modified for the spondylarthropathies (HAQ-S; range 0-3).

5  the Health Assessment Questionnaire for the Spondylarthropathies (HAQS).

6 nkylosing spondylitis (n = 1), and psoriatic spondylarthropathy (n = 1).

7  inflammation plays a pathogenic role in the spondylarthropathy of ankylosing spondylitis (AS).

8 ts that it may play a pathogenic role in the spondylarthropathy of AS.

9 review is to summarize treatment advances in spondylarthropathy over the past year and to discuss pot

10 c arthritis, undifferentiated arthritis, and spondylarthropathy patients also displayed anti-GPI anti

11 plications for a better understanding of the spondylarthropathies (SpA).

12  Spondylarthropathy Study Group criteria for spondylarthropathy (SpA), and 75 (36%) were classified a

13  arthritis (JRA) and pauciarticular/juvenile spondylarthropathy (SpA), respectively.

14 n 28 patients with plantar fasciitis; 17 had spondylarthropathy (SpA)-associated disease, and 11 had

15 osition to ReA and perhaps other subtypes of spondylarthropathy (SpA).

16              Study patients met the European Spondylarthropathy Study Group criteria for SpA, without

17 id arthritis (RA), 38 (18%) met the European Spondylarthropathy Study Group criteria for spondylarthr

18 e HLA-B27 positive, and 98% met the European Spondylarthropathy Study Group criteria.